Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 40HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Gastric Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × pyrotinib × Clear all
NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Tianjin Medical University Second Hospital

Phase 2 Unknown
100 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡